Schmitt Emmanuelle, Krack Paul, Castrioto Anna, Klinger Helene, Bichon Amelie, Lhommée Eugénie, Pelissier Pierre, Fraix Valerie, Thobois Stephane, Moro Elena, Martinez-Martin Pablo
Movement Disorders Unit, Department of Psychiatry Neurology and Neurological Rehabilitation CHU Grenoble Grenoble France.
Grenoble Institut des Neurosciences Grenoble Alpes University France.
Mov Disord Clin Pract. 2018 Mar 23;5(3):265-272. doi: 10.1002/mdc3.12607. eCollection 2018 May-Jun.
Non-motor fluctuations represent a main source of disability in Parkinson's disease (PD). Among them, neuropsychiatric fluctuations are the most frequent and are often under-recognized by patients and physicians, partly because specific tools for assessment of neuropsychiatric fluctuations are lacking.
To develop a scale for detecting and evaluating the presence and the severity of neuropsychological symptoms during the ON and OFF phases of non-motor fluctuations.
Neuropsychiatric symptoms reported by PD patients in the OFF- and the ON-medication conditions were collected using different neuropsychiatric scales (BDI-II, BAI, Young, VAS, etc.). Subsequently, tree phases of a pilot study was performed for cognitive pretesting, identification of ambiguous or redundant items (item reduction), and to obtain preliminary data of acceptability of the new scale. In all the three phases, the scale was applied in both the OFF and ON condition during a levodopa challenge.
Twenty items were selected for the final version of the neuropsychiatric fluctuation scale (NFS): ten items measured the ON neuropsychological symptoms and ten items the OFF neuropsychological manifestations. Each item rated from 0-3, providing respective subscores from 0 to 30.
Once validated, our NFS can be used to identify and quantify neuropsychiatric fluctuations during motor fluctuations. The main novelty is that it could be used in acute settings. As such, the NFS can assess the neuropsychiatric state of the patient at the time of examination. The next step will be to validate the NFS to be used in current practice.
非运动波动是帕金森病(PD)致残的主要原因。其中,神经精神波动最为常见,但患者和医生往往对此认识不足,部分原因是缺乏评估神经精神波动的特定工具。
开发一种量表,用于检测和评估非运动波动的“开”期和“关”期神经心理症状的存在及严重程度。
使用不同的神经精神量表(BDI-II、BAI、Young、VAS等)收集帕金森病患者在“关”期和“开”期服药状态下报告的神经精神症状。随后,进行了初步研究的三个阶段,以进行认知预测试、识别模糊或冗余项目(项目缩减),并获取新量表可接受性的初步数据。在所有三个阶段中,该量表均在左旋多巴激发试验的“关”期和“开”期应用。
神经精神波动量表(NFS)的最终版本选取了20个项目:10个项目测量“开”期神经心理症状,10个项目测量“关”期神经心理表现。每个项目的评分从0到3,各自的子分数从0到30。
一旦经过验证,我们的NFS可用于识别和量化运动波动期间的神经精神波动。主要新颖之处在于它可用于急性情况。因此,NFS可在检查时评估患者的神经精神状态。下一步将是验证NFS在当前实践中的应用。